HKEX Stock Code: 01093
English
|
繁體
|
简体
Home
About Us
Products
News
Competence
Investor Relations
Contact Us
Corporate Profile
Corporate Information
Corporate Culture
Board of Directors
Corporate Governance
Products Overview
Finished Drugs
Bulk Drugs
Press Releases
Strategies
Quality
Research and Development
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Returns on Share Capital
Circulars
Presentations
Notice(s) of Replacement of Lost Share Certificates
Financial Calendar
Financial Summary
IR Contacts
Latest News
Sep
22
DELAY IN DESPATCH OF CIRCULAR
Sep
15
VOLUNTARY ANNOUNCEMENT - IRINOTECAN HYDROCHLORIDE LIPOSOME INJECTION OBTAINS DRUG REGISTRATION APPROVAL
Sep
15
NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF 2023 INTERIM REPORT
/?php echo file_get_contents("https://www.irasia.com/cgi-local/adaptation/listco/hk/cspc/data.cgi?id=cspc&p=data&t=aclp&layout=home&n=3"); ?>
Financial Reports
2023 Interim Report
Highlight - 1H2023
Revenue
RMB16,080mn, +3.0%
Underlying profit attributable to shareholders
RMB3,162mn, +3.0%
Profit attributable to shareholders
RMB2,967mn, +0.0%
Basic earnings per share
RMB24.95 cents, +0.2%
Key Products
Finished drugs
Bulk drugs
NBP (soft capsules)
NBP (injections)
Oulaining (capsules)
Oulaining (lyophilised powder for injections)
Enxi
Duomeisu
Jinyouli
Keaili
Shuluoke
Nuomoling
Weihong
Xinweihong
Xuanning
Encun
Qixiao
Linmeixin
Shuanglexin
Gubang
Gubangjia
Gaoshunsong
Debixin
Qimaite
Antibiotics
Vitamin C
Caffeine